In recent years, interest in apheresis has been growing among people visiting Japanese medical institutions from overseas.
Apheresis is not a single treatment method, although it may be described using various terms such as "blood purification," "plasma exchange," or "blood exchange."
This is a general term for medical technologies that involve circulating blood outside the body, separating blood cells from plasma, and then removing or adjusting specific proteins, autoantibodies, immune complexes, lipids, etc., present in the plasma according to the desired purpose.
While there are already established areas of treatment for autoimmune diseases, neurological disorders, and dyslipidemia, recent research has also focused on its relationship with age-related inflammation and the molecular environment in plasma.
What's important here is that even though the name "apheresis" is the same, the target substance and the removal mechanism differ depending on the equipment, filters, and adsorption columns used.
The blood contains many proteins and immune-related substances necessary for maintaining bodily functions. Therefore, simply removing a large number of substances is not the solution.
The important considerations are what in the blood is being targeted, how it will be removed, and whether there is a medical reason for choosing that method.
This time, we will focus on double membrane filtration plasmapheresis (DFPP) and plasma adsorption (PA), which are representative methods of apheresis, and organize the different approaches depending on the filter and adsorption column, as well as the possibilities from the perspective of personalized medicine.

- Apheresis varies depending on "what to remove".
- Differences between DFPP and plasma adsorption therapy (PA)
- Three types of filters/adsorption columns and their respective targets
- Why is personalized choices important?
- Apheresis and anti-aging research
- Four points to consider when thinking about treatment
- From now on, we'll shift from "blood purification" to "blood profiling."
- Important things when receiving medical treatment from overseas
- Apheresis is a medical technology where the purpose of the procedure is a crucial factor.
Apheresis varies depending on "what to remove".
In general perception, apheresis is often understood as "a method of removing unwanted substances from the body by passing blood through a machine."
However, blood contains a wide variety of components, including lipids, immunoglobulins, autoantibodies, coagulation-related proteins, and albumin. Each of these has a different role, so the type and extent of components removed will vary depending on the blood purification method.
Apheresis primarily employs the following methods:
- Plasma exchange (TPE)A method of reducing various substances in plasma by removing plasma and replenishing it with a replacement fluid or the like.
- Double membrane filtration plasmapheresis (DFPP)This method involves filtering the separated plasma through another membrane to fractionate and remove specific components by utilizing differences in molecular size and other factors.
- Plasma adsorption therapy (PA)A method of adsorbing specific substances by passing separated plasma through an adsorption column, depending on the characteristics of the column.
These are all classified as apheresis, but their mechanisms of action are different.
For example, plasma exchange broadly reduces various substances in the plasma, while DFPP utilizes the separation properties of the membrane, and PA utilizes the properties of the adsorbent.
In other words, to understand apheresis, it is not enough to just know the name of the treatment method,What principles are used, and what are the targets?It is important to know this.

Differences between DFPP and plasma adsorption therapy (PA)
The two approaches I want to focus on this time are DFPP and PA.
DFPP: Utilizes membrane-based fractionation
DFPP is a method that separates plasma from blood and then further fractionates the plasma components by passing them through a secondary membrane.
The configuration described in the attached document uses the "Plasma Flow OP" plasma separator and the "Cascade Flow EC" secondary membrane, both manufactured by Asahi Kasei Medical Corporation.
By processing the plasma in two stages, we aim to fractionate and remove high-molecular-weight regions containing specific components in the plasma, such as LDL cholesterol, triglycerides, and fibrinogen.
However, the substances removed and the extent of removal depend not only on the membrane's properties but also on treatment conditions and the amount of plasma processed. Furthermore, some essential proteins may be lost, making careful treatment design and medical management crucial.
While DFPP is a technology used in the treatment of specific diseases, its potential for modulating age-related factors and its preventative use in healthy individuals should be evaluated separately from the findings obtained from disease treatment.
PA: Utilizing the properties of adsorption columns
On the other hand, PA (Plasma Adsorption) is a method in which plasma separated from blood is passed through an adsorption column, and specific substances are adsorbed according to the characteristics of the column.
This document introduces two types of adsorption columns that target different targets, even though both are used in plasma adsorption therapy.
- PH-350The documentation describes it as a column that selectively adsorbs immune complexes, rheumatoid factors, anti-DNA antibodies, etc.
- TR-350The document describes this as a column that targets anti-acetylcholine receptor antibodies (anti-AChR antibodies).
Thus, even though PA uses the same plasma adsorption mechanism, the target substances differ depending on the characteristics of the column used.
This does not remove all components from the blood,The idea is to select the adsorbent according to the target substance.is.
Please note that the actual indication and column selection must be determined by a physician, taking into account the target disease, the patient's condition, and the approval and usage conditions.

Three types of filters/adsorption columns and their respective targets
Let's organize the differences we've discussed so far, following the equipment configuration presented in this document.
| Components | method | Main target and role |
|---|---|---|
| Cascade Flow EC | DFPP secondary film | By utilizing the separation properties of the membrane, specific plasma components, including LDL cholesterol, can be fractionated and removed. |
| PH-350 | PA adsorption column | Immune complexes, rheumatoid factor, anti-DNA antibodies, etc. |
| TR-350 | PA adsorption column | Anti-acetylcholine receptor antibodies, etc. |
*The above is a summary of the equipment configuration and explanation described in the attached document. The Plasma Flow OP is a primary plasma separator that is introduced in both the DFPP and PA documents. The three types in the table do not all represent the same hierarchical treatment method, but rather represent one type of secondary membrane for DFPP and two types of adsorption columns for PA.
This difference is an important perspective when individualizing apheresis.
For example, the methods and equipment configurations to consider will differ depending on whether you are targeting lipid-related components or specific autoantibodies.
On the other hand, using the same method does not mean that all target substances will be removed to the same degree. Furthermore, the mere existence of filter and column options does not mean that there is a treatment suitable for everyone.
Individualization is not just about increasing the number of options, but about identifying the appropriate options based on medical evidence.
Why is personalized choices important?
Even among people of the same age, blood test results, medical history, medication status, lipid metabolism, and immune system status can vary from person to person.
Therefore, when considering apheresis, it is important to first clarify the objective.
For example, the target components and the rationale for considering treatment differ between treatment for dyslipidemia and treatment for reducing pathogenic substances associated with autoimmune diseases.
Furthermore, when considering treatment from the perspective of health maintenance or factors related to aging, a different perspective is needed than that for treating the disease itself. A change in test values does not necessarily mean that the change will lead to long-term improvement in health.
The pre-treatment evaluation should confirm at least the following points:
- What is the purpose of considering this treatment?
- Are there any medically noteworthy findings from blood tests, etc.?
- Is there a treatment method suitable for the target substance?
- Has the impact on necessary plasma components, as well as the components to be removed, been considered?
- Are you able to compare the expected benefits with the risks related to bleeding, hypotension, and vascular access?
The most important thing is not to start by thinking of treatment as the only option.
Depending on the test results, it may be necessary to prioritize treatments other than apheresis or lifestyle modifications.

Apheresis and anti-aging research
In recent years, research into the relationship between apheresis and aging has been conducted based on studies showing that proteins and inflammation-related factors in plasma are involved in various tissues and functions of the body.
Chronic inflammation associated with aging is called "inflammaging," and research is also being conducted on SASP (Senescence-Associated Secretory Phenotype) and inflammatory cytokines that are secreted in connection with cellular senescence.
Apheresis, which physically reduces or modifies components in plasma, is attracting attention as one approach for studying these molecular environments.
However, a clear distinction is necessary here.
Even if it's possible to reduce the levels of a specific substance in the blood, that alone doesn't necessarily mean that aging itself can be suppressed. Furthermore, the fact that a particular substance is associated with a disease, and that removing that substance from the blood reduces the risk of that disease, are separate issues.
The explanatory materials for DFPP list LDL, oxidized LDL, advanced glycation end products (AGEs), and inflammation-related substances as relevant keywords. However, it is not possible to conclude from these descriptions alone how much of each substance is removed by the filter used, or whether anti-aging effects can be obtained.
Furthermore, research findings regarding the impact of apheresis on biological age-related markers in healthy individuals are inconsistent.
Therefore, at this stage, rather than positioning apheresis as a general "rejuvenation treatment,"We are currently researching the effectiveness and limitations of this technique as a way to modify the molecular environment in plasma.That would be the most appropriate interpretation.
Going forward, it will be necessary to investigate which substances should be targeted, which methods are appropriate, how long the changes after treatment will last, and whether it will lead to clinically meaningful health benefits.

Four points to consider when thinking about treatment
1. Is a medical evaluation performed before treatment?
The basic approach involves reviewing blood tests, medical history, medication status, liver and kidney function, complete blood count, and coagulation system, as needed, to determine the appropriateness of treatment.
If the goal is to remove a specific substance, then the appropriate tests related to that substance must be selected.
2. Can you explain the different methods?
DFPP and PA use different mechanisms for separating and removing substances. Furthermore, even with the same method, like PA, the target substance may differ depending on the adsorption column.
It's important to receive an explanation not only of which method will be used, but also of why that method was chosen and what it targets.
3. Is there a well-established specialized medical system?
Because apheresis utilizes extracorporeal circulation, it requires management of vascular access, blood flow rate, anticoagulation, and circulatory status.
In addition to the doctor's examination, it's also important to check the experience and collaboration of other medical staff involved in treatment, such as clinical engineers and nurses.
Furthermore, depending on the medication you are taking, there may be therapeutic precautions or contraindications. Do not stop taking your medication on your own; you must always consult a doctor.
4. Are changes after treatment being appropriately evaluated?
Even if blood test values change before and after treatment, the extent to which those changes persist and what impact they have on one's health needs to be evaluated separately.
It is important not only to record the values immediately after treatment, but also to conduct follow-up examinations and monitoring as needed, and to record the results.
Especially when considering these measures for preventative or anti-aging purposes, it is crucial to avoid confusing short-term changes in test values with long-term health benefits.
From now on, we'll shift from "blood purification" to "blood profiling."
One interesting approach to consider for the future of apheresis is the idea of combining blood tests with treatment.
In recent years, advances in technologies such as proteomics have led to research that comprehensively analyzes the numerous proteins present in plasma.
These technologies may, in the future, allow us to understand individual protein characteristics, inflammation-related factors, and metabolic factors in more detail.
The process involves interpreting that information medically and considering appropriate treatment if necessary.
Examination → Medical evaluation → Selection of treatment method → Post-treatment examination → Follow-up
This cycle is important because it not only allows us to choose a treatment based on the test results, but also to evaluate afterward whether that choice was appropriate.
However, being able to measure a large number of substances in the blood does not mean that the optimal removal method for each substance has been established.
High levels of a particular protein do not necessarily necessitate apheresis, nor is it always beneficial to remove that substance.
The combination of blood profiling and apheresis represents an interesting direction for future personalized medicine, but actual clinical application requires verification of the interpretation of test results and the effectiveness of treatment.
Important things when receiving medical treatment from overseas
For those coming from outside Japan to receive apheresis, not only the treatment method and facilities are important, but also the pre-treatment information gathering and post-treatment follow-up.
By sharing information such as your medical history, current medications, past test results, and treatment goals in advance, doctors can gather the necessary information to assess the appropriateness of your treatment.
It is also important to record the results of post-treatment tests and the procedures performed, so that you can share them with your doctor upon returning to your home country if necessary.
Apheresis is not something that can be performed in the same way by anyone, even if they have the necessary equipment.
It is essential to understand which method will be used, what the target is, and what risks are involved, and then seek a doctor's opinion at an appropriate medical institution.
Apheresis is a medical technology where the purpose of the procedure is a crucial factor.
Apheresis has established applications as a treatment for autoimmune diseases, neurological disorders, and dyslipidemia, but its relationship with aging and chronic inflammation is still under investigation.
Its key feature is that, rather than uniformly removing components from the blood, it allows for the consideration of an approach tailored to the specific objective by utilizing the separation characteristics of the membrane and the properties of the adsorption column.
DFPP and PA have different removal mechanisms, and even within PA, the target substances differ depending on the column, such as PH-350 and TR-350.
However, simply having multiple options does not automatically mean that personalized treatment will be achieved.
The important thing is to conduct a medical evaluation, clearly define what the treatment targets, compare the expected benefits with the risks, and then choose the appropriate method. Furthermore, it's crucial to objectively evaluate the changes after treatment and use that information for subsequent health management as needed.
Rather than simply "cleaning" the blood, we aim to understand its components and consider appropriate methods when necessary.
When considering the potential of apheresis, what's important is not how much substance can be removed, but rather the medical perspective of what the purpose is and why that method is chosen.

Comment